Deep Value Report Centene Corporation (NYSE: CNC)
1) Executive Summary
Centene just lived through the kind of quarter that chases away momentum traders and invites operators who think like pilots.
On July 1, 2025 the company withdrew full-year 2025 guidance, signaling that both its ACA Marketplace book and Medicaid trend
were running hotter than modeled. On July 25, Centene reported second-quarter results: a net loss, a health benefits ratio (HBR)
of 93.0% versus 87.6% in the year-ago period, and a reset of the 2025 earnings framework to approximately $1.75 of adjusted EPS
(with a downside contingency of $1.25 if trends deteriorate). The stock reacted violently to the withdrawal and then partially
stabilized once the magnitude of the reset and the remediation plan were placed on the table.
Our deep value lens is simple. First, Medicaid and Marketplace are not speculative businesses; they are regulated programs with
enduring political and economic mandates. When utilization or risk acuity surprises to the upside, the mechanism is not to
eliminate the program but to reprice it. Second, Centene’s core asset is not a single factory or patent—it is a scaled platform
for contracting, pricing, clinical operations, pharmacy management, and state-level execution. The “engine” is the rate file, the
data flowing into it, and the cadence of negotiations with state actuaries and Exchange regulators. Third, the calendar matters.
Across the July 1 to January 1 window that spans the back half of 2025, management expects roughly eighty‑eight percent of the
Medicaid book to be re-rated as states true-up capitation for observed trend. That window, combined with already-filed premium
refiles in the ACA Marketplace for 2026, is the bridge from today’s pain to tomorrow’s normalization.
This is not a story about whether healthcare costs will be high; they will. It is a story about price following trend with a lag.
The market priced the lag; deep value is buying the catch-up. Our report proceeds as follows: we frame the business model and
policy context; we walk through what went wrong and why it felt sudden; we quantify the balance sheet and cash profile; we surface
the “hidden assets” that don’t sit neatly on a line of the financial statements; and we spell out a practical scenario tree for
2026–2027 that ties contract re-rating to HBR normalization and EPS rebuilding. Along the way, we keep the tone you asked for:
direct, disciplined, checklists over narratives, with occasional humor—the kind you earn after twenty years of flying where
the only acceptable error rate is zero.
2) Business Model, Moat, and Why Scale Matters
Centene is a managed-care platform focused on government-sponsored healthcare: primarily Medicaid managed care and the individual
ACA Marketplace, with a smaller but meaningful Medicare footprint and a large stand‑alone prescription drug plan (PDP) book.
Unlike a fee-for-service insurer, a managed-care organization (MCO) accepts a fixed premium (capitation) per member per month and
assumes the risk of paying for covered services. The economic engine is a spread: premium minus medical claims (the medical loss
ratio, or HBR/HCR at Centene) minus operating costs (SG&A) equals underwriting margin. Scale matters because (1) it enables
pricing and product in many states, (2) it creates leverage in pharmacy procurement and specialty-drug management, (3) it
improves the fidelity and timeliness of data flowing into rate negotiations, and (4) it supports clinical programs that blunt
trend (behavioral health integration, complex case management, social determinants interventions).
Medicaid is ultimately a state-by-state business. Each state’s actuarial team certifies that capitation rates are “actuarially
sound,” subject to federal CMS guardrails. In normal times, that means capitation changes slowly. In periods like 2024–2025—when
utilization, acuity, and pharmacy trend shift quickly—states push through larger mid-cycle or next‑cycle adjustments. The key for
any MCO is to show credible, current data that the actuary can lift into the certified rate. That is why management emphasized
accelerating the “data cadence” into state processes after the Q2 miss. The process is administrative rather than political,
but timing and documentation are everything.
On the ACA Marketplace side, the mechanics are different. Premiums are filed annually, and a federal risk‑adjustment mechanism
transfers funds from plans with lower-risk membership to plans with higher‑risk membership. When morbidity in a state pool rises
faster than a given plan’s premium assumptions, two things can happen: (1) the plan receives more risk‑adjustment revenue if its
membership is sicker than the market, or (2) it pays more into the pool if relative risk is lower. In 2025, Centene faced the
twin hit of higher-than-modeled medical trend and an unfavorable net risk-adjustment position across a number of states; that is
what drove the sudden EPS reset. The correction lever is a 2026 premium refiling that “prices to reality.”
The punch line: this business has a bad year when the meter moves faster than the rate. But the meter and the rate converge over
the following cycle, and the longer the gap persists, the larger the adjustment. Deep value lives in that gap, provided the
platform can bridge the cash and maintain contract credibility while the re-pricing arrives.
3) What Went Wrong in Q2’25—and Why It Looked Abrupt
Two forces converged. First, on the ACA Marketplace, risk‑adjustment transfers and medical costs came in worse than Centene’s
spring modeling indicated. External summaries pegged the revenue shortfall at roughly the low‑to‑mid single billions across the
industry, with Centene’s specific impact amounting to an EPS headwind of roughly two‑plus dollars for 2025. Second, Medicaid
costs rose in categories that are difficult to quickly bend: behavioral health, home health, and high‑cost drugs (including GLP‑1
therapies and specialty pharmacy). Each of these lines has secular momentum—utilization isn’t a switch you can flip. When they
move together within the same quarter, the HBR response is blunt: up and to the right.
HBR printed at 93.0% in Q2’25 versus 87.6% a year earlier. SG&A ran at approximately 7.1%, roughly flat on an adjusted basis,
meaning the P&L damage was overwhelmingly medical. Management withdrew guidance on July 1 to set expectations and returned on
July 25 with a reset (about $1.75 of 2025 EPS, with a $1.25 contingency), plus a clear plan: accelerate rate relief on Medicaid,
refile 2026 Marketplace premiums with current morbidity, and use cash discipline to traverse the interim. That is how a pilot
handles turbulence: get the nose level, find clean air, and fly the plan, not the noise.
4) Membership Mix and the Exchange/Medicaid Bridge
Redeterminations continue to trim Medicaid enrollment as states reconfirm eligibility post‑public health emergency, while the ACA
Marketplace absorbs some of those lives. Centene’s book shows exactly that dynamic: Medicaid membership modestly lower year over
year but Marketplace membership higher. The bridge matters because it preserves lives within the platform even as funding sources
change; however, it also changes the revenue mechanics—on Exchange, your premium and net risk‑adjustment position carry the day.
Below we chart the membership shift from Q2’24 to Q2’25. The rise in Marketplace is visible; the drop in Medicaid is the other
side of the see‑saw. The strategic task for 2026 is to hold the lives while rerating the price on both sides of the bridge.
Visual: Membership Shift (Q2’24 → Q2’25)
5) HBR, EPS, and Why 2025 Is a Transition Year
The HBR spike to 93.0% is the number that tells the story. An MCO can accept a tough quarter; what the market fears is that the
tough quarter becomes the new base. Centene’s argument—and ours—is that 2025 is a transition year in which rates and premiums
play catch‑up to trend. In the Medicaid segment, that catch‑up runs through the **July/October/January** re‑rate window. In the
ACA segment, it runs through **2026 filings** that incorporate current morbidity.
We chart the HBR progression year over year and the 2025 EPS reset to illustrate how management reframed the year. The frames are
not comforting in isolation; they are clarifying in context. Once you accept that 2025 is a reset, the investment question becomes
whether the **mechanics of re‑pricing** are credible and sufficiently large to move HBR back into the high‑80s in 2026. Our read:
the mechanics are visible, and the calendar is your ally.
Visual: HBR Trend & 2025 EPS Reset
6) The ‘September’ Re‑Rate Window—Mechanics You Can Model
Medicaid capitation is certified by state actuaries under CMS guidance. In August 2025, CMS published the **2025–2026 Rate
Development Guide**, covering rating periods beginning July 1, 2025 through June 30, 2026. States with July 1 fiscal years
(NC is a common example) often finalize updated capitation for a July 1 effective date; others key off October 1; and still
others implement adjustments prospectively on January 1 after the paperwork clears. That is why “September” shows up in
investor conversations: it is the month when the last mile of actuarial certification, budget alignment, and contract
amendments tend to crystallize for October and January application.
Centene’s management stated that **approximately eighty‑eight percent** of its Medicaid book is scheduled to be re‑rated
between **July 1, 2025 and January 1, 2026**. When you combine that breadth with the obvious, documented drivers of cost
(behavioral, home health, high‑cost drugs), the actuarial case for meaningful capitation uplifts is straightforward. No one
claims that rates always match trend one‑for‑one, but the direction is unlikely to be ambiguous when data are current and
persistent. The other lever is service carve‑outs and benefit adjustments; some states respond not only with dollars but with
design changes to target the cost drivers.
We include a simple visual reminder below: the re‑rate coverage is broad and time‑bound, which is precisely the setup you want
when you’re underwriting HBR normalization into 2026.
Visual: Medicaid Contracts Re‑rated by Jan 1, 2026
7) Financial Profile—Cash, Investments, Debt, and Claims Discipline
A deep value investor’s first instinct is to check the fuel and the gauges. On that count, Q2’25 offered reassurance beneath the
headline P&L. Operating cash flow registered approximately $1.8 billion (helped by pharmacy rebate timing), total cash and
investments plus restricted deposits approximated $37.5 billion (with the vast majority regulated at the health plan level),
and total debt stood near $17.6 billion with the corporate revolver undrawn. Days in claims payable (DCP) measured **47**—down
two days from Q1 due to timing and state‑directed payments—but still within a disciplined band. In short, liquidity is intact,
claims payment discipline is in place, and the balance sheet is built for the re‑rating slog.
There is an understandable temptation to compare managed‑care leverage to industrial capital structures. It is the wrong
analogy. Regulated capital at the plan level is constrained by risk‑based capital (RBC) requirements, not a simple net‑debt‑
to‑EBITDA lens. Cash and investments sit in regulated entities for a reason, and intercompany flows must respect statutory
guardrails. The relevant test is whether the enterprise has the cash‑flow durability and regulatory headroom to ride through a
rate‑lag year without compromising service, networks, or state relationships. The answer in Centene’s case is yes.
8) Hidden Assets—What the Financial Statements Don’t Name
You asked for “hidden assets,” the kind we highlighted in old‑economy names. Payers have them too—just not in the way a REIT or
a steel mill does.
• **The rate engine**. The capability to ingest fresh claim lines, pharmacy trend, vendor pricing, and acuity signals into an
actuarially credible rate narrative is the managed‑care equivalent of a low‑cost plant. States will not pay you because you ask;
they will pay if you can prove trend and demonstrate control levers that make future dollars buy better outcomes. Centene’s
history of securing outsized rate increases in high‑trend windows is not an accident; it reflects this engine.
• **The bridge across programs**. A dual footprint in Medicaid and Marketplace is an asset. It preserves enrollment continuity
when eligibility shifts and offers states an integrated set of tools (e.g., care management programs that touch members in both
venues). The Marketplace pain of 2025 is a pricing issue, not a capability failure; the ability to retain lives and then charge a
2026 price that maps to morbidity is a quiet asset.
• **Pharmacy scale and PDP reach**. With roughly 7.9 million PDP members and substantial Medicaid/Marketplace pharmacy spend,
Centene is a price‑maker, not a price‑taker, in many drug categories. That leverage surfaces in rebates, preferred networks, and
clinical pathways that reduce waste. It is also the reason pharmacy timing can swing quarterly cash flow—leverage is power, and
power must be reconciled with counterparties on a calendar.
• **State relationships**. Procurement history is an intangible moat. States remember who stood up networks in tough counties,
who ran behavioral programs that avoided ER spikes, and who invested in social determinants infrastructure. That narrative is not
immediately legible in GAAP, but it informs re‑procurement scores and rate credibility when conditions tighten.
• **Claims infrastructure**. DCP discipline (47 days in Q2) and low‑variance claims operations are operational assets. In a spike
year, the ability to pay clean claims quickly while contesting outliers is a competitive advantage with both providers and state
regulators.
9) Catalysts—From September to 2027
Near term (Q3–Q4 2025):
• **Medicaid re‑ratings** across the late‑summer to winter window. Expect partial relief flowing into October start dates and a
final wave into January. The September checkpoint is where we expect the most state letters and actuarial certifications to hit.
• **Marketplace 2026 refiles**. Premium filings that explicitly incorporate observed morbidity will reset Exchange economics.
• **Narrative stabilization**. After a guidance withdrawal, the first step is to put numbers back on the wall and show monthly
trend stabilizing. We will watch Medicaid HBR directionality and Exchange risk‑adjustment commentary in the Q3 call closely.
Medium term (2026):
• **HBR normalization**. The combination of capitation uplifts and repriced Exchange premiums should move consolidated HBR back
toward target ranges. Not every state and every line will move in lockstep, but the breadth of the rerating window argues for a
visible aggregate effect.
• **Mix stabilization**. Redetermination headwinds ease; Marketplace growth moderates toward a more sustainable base. Pharmacy
contracts roll forward with lessons learned from 2025.
Longer term (2027+):
• **Margin rebuild**. Once the lag closes, the model reverts to spread management: price over trend with operating discipline.
The path to normalized EPS is a function of how much price is captured and how sticky the high‑trend categories remain. Even in a
world of chronic high utilization, the value of the platform rises if the enterprise can turn trend into rate without losing
share or service performance.
10) Scenarios—Downside, Base, Upside (and What We’d Need to See)
We frame three scenarios with operational triggers rather than only EPS targets, because in managed care the “how” often matters
as much as the “how much.”
**Downside (“Slow Re‑rate”)**. States move more slowly than anticipated; October uplifts are lighter, and January is the main
adjustment. Marketplace 2026 filings are accepted but conservative. HBR remains stuck near 90–92% through mid‑2026 before
improving. Cash is fine, but sentiment stays fragile. What would we watch? Early state letters in September/October, any sign of
retro treatment for first‑half trend, and Q3 medical cost development (especially behavioral/home health lines).
**Base (“On‑Plan Re‑rate”)**. A meaningful subset of states implement October uplifts, with the remainder effective Jan 1.
Marketplace 2026 rates come in strong enough to reflect morbidity. Consolidated HBR walks down sequentially in 2026; EPS
rebuilds accordingly. By late 2026, investors have shifted the debate from “can they fix it?” to “what is the normalized margin?”
**Upside (“Front‑Loaded Correction + Mix Help”)**. States provide outsized October increases in several large programs and allow
retro components for documented first‑half spikes; January sweeps mop up the rest. Marketplace 2026 premiums are approved at the
upper end of the range. Medicaid redetermination drift slows faster than modeled. Pharmacy initiatives reduce net trend more than
expected. HBR returns to high‑80s by mid‑2026; valuation re‑rates ahead of the printed numbers.
11) Risks—Name Them So They Don’t Own You
• **Rate‑lag persistence**. The core risk is not that programs vanish but that corrections are too small or too late. Mitigation:
data cadence, actuarial documentation, and a wide rerate window (July–January) covering ~88% of the book.
• **Marketplace risk‑adjustment volatility**. RA is a seesaw. Even with higher premiums, relative risk can shift if competitors
change networks or pricing strategies. Mitigation: pricing to morbidity and careful network strategy.
• **Utilization stickiness**. Behavioral health, home health, and GLP‑1/specialty drugs are secular. Even with capitation uplifts,
trend can outrun rate if assumptions trail reality. The hedge is continuous filing discipline and clinical programs with proven
ROI.
• **Policy noise**. State budgets, work requirements, or administrative shifts can introduce friction. Historically, Medicaid and
Exchanges survive policy turns; the economics re‑index.
• **Litigation & headline risk**. Post‑reset lawsuits or investigations are part of the background. They affect sentiment more
than cash flow. Execution still drives equity value.
12) Valuation—How a Deep Value Investor Can Anchor the Work
A classic industrial NAV won’t capture the value of an MCO; what matters is normalized spread and cash conversion. We propose two
anchors: (1) a **normalized HBR framework** that translates state and line‑of‑business rate actions into a consolidated HBR path
for 2026–2027; and (2) a **through‑cycle cash‑to‑EPS bridge** that cross‑checks accrual with cash generation (sensitive to rebate
timing, DCP movements, and working capital).
Practically, in a year like 2025, we lean harder on **scenario weights** than on single‑point EPS. The presence of a large rerate
window with high coverage (88%) argues for assigning non‑trivial probability to the base case. If September/October letters are
tangible and sized, we can shift weight toward the upside. Conversely, if letters are thin and January looks like the only game
in town, we keep the base but haircut the pace of HBR normalization. The point is not to produce a false sense of precision; it
is to keep the checklist updated so that portfolio weight reflects execution reality.
13) Monitoring Checklist—What to Track Each Month/Quarter
• **State activity**. Letters, actuarial certifications, and any mention of retro treatment for first‑half 2025 trend.
• **Q3/Q4 medical costs**. Direction in behavioral health, home health, and specialty drugs vs. Q2 peak.
• **Exchange 2026 filings**. Final approvals and any notable competitor behavior.
• **Cash flow**. Pharmacy rebate timing normalizing; regulated vs. unregulated balances.
• **DCP**. Discipline in claims processing (target a stable 45–50 day band absent one‑off timing).
• **Procurement and renewals**. Any notable wins/losses; shift in mix (ABD/MLTSS/D‑SNP) that changes risk profile.
14) Closing—Pilot’s Call
Risk and Inversion: Medicaid repricing, morbidity spikes, or a goodwill impairment can cut earnings power faster than expected. If policy tailwinds flip, the multiple compresses. Inversion: assume margins erode — even then, CNC’s scale and government contracts anchor a floor. The bet is that normalization outweighs the drag.
A shock quarter does not define a franchise; the response does. Centene’s response is procedural rather than rhetorical: feed
current data into state actuarial processes, secure capitation that reflects observed trend, refile Marketplace premiums for 2026,
and maintain claims discipline and liquidity while the fix lands. The calendar—July, October, January—is not a slogan; it is the
mechanism by which the model reverts toward target.
You asked us to write like we invest: checklists, no drama, reality over narrative. The reality is that managed care’s engine is
the rate file. When the environment changes quickly, the lag hurts; when the apparatus catches up, the spread returns. Our view
is that 2025 is the hurting; 2026–2027 are the catching‑up. If early fall letters come through at scale, the equity should begin
to discount the normalization well before the HBR prints. That is the deep value setup: buying the re‑pricing rather than buying
the problem.
15) State-by-State Medicaid Dynamics
To understand why the “September window” matters, you need to see how states run their fiscal calendars.
Many operate on July 1 fiscal years, which means their Medicaid capitation resets are certified by actuaries in the late summer.
For example, North Carolina’s Medicaid program has historically implemented new capitation rates effective July 1, which then flow
through for the entire fiscal year. California often updates capitation quarterly but aligns larger adjustments with October 1 or
January 1 starts. Texas has experimented with mid‑year adjustments when high‑cost drugs disrupt actuarial soundness. The diversity
is real, but the common theme is that by September–October, most of the actuarial certifications for the next twelve months are
done or close to final. That is why management emphasizes the fall as the inflection point for re‑rating. With roughly 88% of
Centene’s Medicaid book due for re‑rating between July and January, the breadth of the coverage across geographies provides
confidence that aggregate HBR will shift back in the right direction.
16) ACA Risk Adjustment Primer (Toy Example)
The ACA Marketplace risk‑adjustment program redistributes funds between insurers based on the relative morbidity of their
enrolled members. Imagine a simple example: Plan A and Plan B both enroll 100 members. If Plan A’s members are mostly healthy
while Plan B’s members are mostly sick, the program transfers dollars from A to B to compensate. In 2025, Centene found itself
on the wrong side of this balance in several states: its relative risk score was lower than the state average, meaning it had
to pay into the pool rather than receive. The net impact was a negative swing in revenue recognition amounting to billions.
The fix is not theoretical: for 2026, Centene is refiling premiums in those states to incorporate observed morbidity, meaning
that if the pool remains sicker, the premium revenue will be aligned. The key is that RA is a relative game: if competitors
misprice or miscode, Centene’s position can improve. What looked like a structural impairment is in fact a one‑year mismatch
between morbidity, pricing, and relative RA position.
17) Scenario Model: HBR/EPS Walk-Down for 2026–2027
We can translate the rate‑relief narrative into numbers. Assume consolidated HBR at 93% in Q2’25. If October re‑rates in major
states deliver 200–300 basis points of relief and January sweeps add another 200 bps, consolidated HBR could be trending back
toward 89% by mid‑2026. Add another year of Exchange premium increases catching up to morbidity, and HBR could settle in the
high‑80s by 2027. On EPS, that could mean moving from $1.75 in 2025 to $4–5 in 2026 and potentially $6–7 in 2027, assuming
SG&A discipline and no major new shocks. These are not guarantees, but they frame the cadence: 2025 = pain, 2026 = partial
normalization, 2027 = rebuilt run rate. That is the deep value arc.
18) Appendix: Glossary & Regulatory Timeline
• **HBR (Health Benefits Ratio)**: Medical costs as a % of premium revenue. Target high‑80s for profitability.
• **RA (Risk Adjustment)**: ACA mechanism shifting dollars between plans based on morbidity.
• **Redeterminations**: State reviews of Medicaid eligibility post‑COVID emergency.
• **DCP (Days in Claims Payable)**: Indicator of claims payment discipline.
• **Capitation**: Fixed payment per member per month to an MCO for covered services.
• **CMS Rate Development Guide**: Annual CMS publication outlining standards for state actuaries to certify Medicaid rates.
**Regulatory Timeline (relevant to Centene 2025–2026):**
- **June 2025**: CMS publishes ACA RA results for 2024 benefit year.
- **July 2025**: First wave of Medicaid re‑ratings effective. Centene withdraws guidance.
- **September 2025**: States finalize capitation adjustments for October starts.
- **October 2025**: Second wave of Medicaid re‑ratings effective.
- **January 2026**: Final sweep of Medicaid re‑ratings (~88% of book completed).
- **April 2026**: Centene reports Q1 with first quarter of materially re‑rated Medicaid + repriced Marketplace premiums.